Ritter Pharma (RTTR) Announces Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of Gut Microbiome
Tweet Send to a Friend
Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) announced today that its lead drug, RP-G28, promoted beneficial adaptation of the gut microbiome ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
